Evidence map›Paper›PMID 32361788›Full record

ArticleInvestigational new drugs2020

The near-infrared fluorescent dye IR-780 was coupled with cabazitaxel for castration-resistant prostate cancer imaging and therapy.

Yu Zheng, Guangdong Hou, Geng Zhang, Ting Lan, Jiarui Yuan, Lei Zhang, Fei Yan, Fuli Wang, Ping Meng, Xinlong Dun and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Investigational new drugs, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 2 countries.

Yu Zheng *Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Guangdong Hou *Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Geng Zhang *Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Ting Lan *Department of Chemistry, School of Pharmacy, Fourth Military Medical University, Xi'an, Shaanxi, China.
Jiarui YuanSt. George's University School of Medicine, St. George's, West Indies, Grenada.
Lei ZhangDepartment of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Fei YanDepartment of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Fuli WangDepartment of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Ping MengDepartment of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Xinlong DunDepartment of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Xi'an LiDepartment of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Guo ChenState Key Laboratory of Cancer Biology, Department of Pharmacogenomics, Fourth Military Medical University, Xi'an, Shaanxi, China.
Zheng ZhuDepartment of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Di WeiDepartment of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Wei HeDepartment of Chemistry, School of Pharmacy, Fourth Military Medical University, Xi'an, Shaanxi, China. weihechem@fmmu.edu.cn.
Jianlin YuanDepartment of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China. jianliny@fmmu.edu.cn.
Xijing Hospital · CNAir Force Medical University · CNSt. George's University · GD

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A new drug, Caba-780, was synthesized by chemical coupling of the heptamethyl phthalocyanine near-infrared fluorescent (NIRF) dye IR-780 and the paclitaxel-based chemotherapeutic drug cabazitaxel. Then, the potential value of Caba-780 in the diagnosis and treatment of castration-resistant prostate cancer (CRPC) was evaluated. The CRPC cell lines DU145 and PC-3, as well as the normal human prostate stromal cell line WPMY-1, were used to evaluate the uptake of Caba-780 and its antitumor effect in vitro. The distribution, antitumor effect, and safety of Caba-780 were also evaluated in tumor-bearing mouse xenograft models. Our results showed that Caba-780 was efficiently absorbed by DU145 and PC-3 cells and that the cytotoxicity of Caba-780 was significantly stronger than that of IR-780 and cabazitaxel. In addition, Caba-780 inhibited the migration and invasion of DU145 and PC-3 cells and promoted apoptosis by prolonging the G2 phase of the cell cycle. Further analysis indicated that Caba-780 could be used to effectively image tumor xenografts. At the same time, this drug inhibited the growth of tumors in vivo. Therefore, the new synthetic drug Caba-780 has potential applications in the diagnosis and treatment of CRPC.

Indexed as

AnimalsAntineoplastic AgentsApoptosisCell CycleCell LineCell MovementCell SurvivalFluorescent DyesHumansIndolesMaleMice, NudeProstatic Neoplasms, Castration-ResistantTaxoids2-(2-(2-chloro-3-((1,3-dihydro-3,3-dimethyl-1-propyl-2H-indol-2-ylidene)ethylidene)-1-cyclohexen-1-yl)ethenyl)-3,3-dimethyl-1-propylindoliumAntineoplastic AgentscabazitaxelFluorescent DyesIndolesTaxoidsCastration-resistant prostate cancerChemotherapyNear-infrared fluorescent dyeOrganic anion-transporting polypeptide

Identifiers

PMID32361788
OpenAlexW3022849258

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.